Share this:

Like this:

This is a guest post from Mark D. Shtilerman1 and Joseph Eng Jr. Dr. Shtilerman is Senior Counsel at Deerfield Management, and Dr. Eng is Counsel at Hogan Lovells. … the very first official thing I did, in my administration … was to start a patent office; for I knew that a country without a […]

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. The run-up to Christmas in Italy is a magical experience, and a great time to revisit Italian agricultural biotechnology. Readers of this irregular series may recall an earlier entry on […]

Share this:

Like this:

The latest on what the Trump presidency means for health care, hospitals, drug companies, and medical research. Tuesday, Nov. 15 The big news right now Even if Trump ends up being a friend to pharma, the private sector – and particularly pharmacy benefit managers – are set to put increasing pressure on drug prices. (Bloomberg) […]

Like this:

The pharmaceutical industry is regularly chastised for failing to do enough to ensure that people in low and middle-income countries have access to its medicines. Yet the real picture is actually more nuanced, according to a newly released report that finds some – but not all – drug makers are making headway. Some companies, for […]